ClinicalTrials.gg
TerminatedNCT02731742Updated Feb 4, 2019Results posted

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

A Phase 1 interventional study of MK-1966 and SD-101 in Neoplasms, Advanced, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This was a non-randomized, open-label study of MK-1966 used in combination with SD-101 in the treatment of advanced malignancies. The study included an initial Dose Evaluation phase (Part A) to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) by evaluating Dose Limiting Toxicities (DLTs) of four dose combinations of MK-1966 and SD-101. Following determination of the MTD/MAD, approximately 20 participants each were to be enrolled in two expansion cohorts (Parts B or C) to confirm/refine the MTD/MAD. The study was terminated by the Sponsor before enrollment into Part A concluded and before enrollment into Parts B and C began.

02

Conditions studied

  • Neoplasms, Advanced

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 14 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a - or cytologically-confirmed advanced that has progressed after standard-of-care therapy/treatments and there is no available therapy likely to convey clinical benefit
  • Has an (ECOG) Performance Status of 0 or 1
  • Has a ≥ 6 months
  • Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test at screening and again within 72 hours prior to receiving the first dose of study therapy)
  • Female and male participants of must agree to use adequate during the course of the study through 120 days after study the last dose of study therapy
  • Has ability to submit archived or fresh tumor sample during the screening period

Exclusion criteria

Exclusion Criteria:

  • Has had chemotherapy, radiation, or biological cancer therapy within 4 weeks prior to the first dose of study therapy, or who has not recovered to (CTCAE) grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks earlier
  • Has participated in a study of an agent and received study therapy or used an investigational device within 28 days of study start
  • Is expected to require any other form of antineoplastic therapy while on study
  • Is on chronic systemic therapy in excess of replacement doses, or on any other form of medication
  • Has a history of a , unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has had a severe reaction to treatment with another monoclonal antibody
  • Has an active disease that has required systemic treatment in past 2 years
  • Has an active infection requiring therapy
  • Has active, current pneumonitis, or a history of (non-infectious) pneumonitis that required steroids
  • Has had a prior stem cell or bone marrow transplant
  • Is positive for (HIV) and/or or C
  • Has known psychiatric disorder that would interfere with fulfilling the requirements of the study
  • Is a regular user of any illicit drugs or had a recent history of substance abuse
  • Has symptomatic ascites or pleural effusion
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study
  • Has heart disease that affects normal activities
  • Has had major surgery (requiring at least a 3 day hospital stay) in the past 28 days
  • Has received a within 30 days prior to first dose of study therapy
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Dose A MK-1966 + Dose A SD-101

    Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.

    Biological: MK-1966 · Drug: SD-101

  • Experimental
    Dose A MK-1966 + Dose B SD-101

    Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.

    Biological: MK-1966 · Drug: SD-101

  • Experimental
    Dose B MK-1966 + Dose B SD-101

    Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.

    Biological: MK-1966 · Drug: SD-101

  • Experimental
    Dose C MK-1966 + Dose B SD-101

    Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.

    Biological: MK-1966 · Drug: SD-101

  • Experimental
    Part B Expansion Cohort

    Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.

    Biological: MK-1966 · Drug: SD-101

  • Experimental
    Part C Expansion Cohort

    Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.

    Biological: MK-1966 · Drug: SD-101

Interventions

  • BiologicalMK-1966

    MK-1966 administered as an intravenous (IV) infusion

  • DrugSD-101

    SD-101 administered as an intratumoral (IT) injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Dose Limiting Toxicity (DLT)

    The occurrence of any of the following toxicities during Cycle 1 (Days 1-21), if assessed by the Investigator to be possibly, probably or definitely related to MK-1966 or SD-101, was considered a DLT: 1. Grade (Gr) 4 non-hematologic toxicity; 2. Gr 4 hematologic toxicity lasting \>7 days, except thrombocytopenia: \*Gr 4 thrombocytopenia of any duration; \*Gr 3 thrombocytopenia if associated with bleeding; 3. Gr 3 non-hematologic toxicity lasting \>3 days despite optimal supportive care; 4. Any Gr 3 or Gr 4 non-hematologic laboratory abnormality, if: medical intervention is required OR abnormality leads to hospitalization OR abnormality persists for \>1 week; 5. Febrile neutropenia Gr 3 or Gr 4; 6. Any drug-related AE which caused participant to discontinue study drug during Cycle 1 7. Gr 5 toxicity; or 8. Delay in initiation of Cycle 2 for \>2 weeks due to study drug-related toxicity. The percentage of participants who experienced a DLT during Cycle 1 is presented.

    Time frame: From time of first dose of study drug to the end of Cycle 1. Each cycle was 21 days. (Up to 21 days)

  2. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study drug, was also an AE. The number of participants who experienced as AE is presented.

    Time frame: From first dose of study drug through 90 days after last dose of study drug (Up to approximately 22 weeks)

  3. Number of Participants Discontinuing Study Drug Due to AEs

    The number of participants who discontinued study drug due to an AE is presented.

    Time frame: From first dose of study drug up to last dose of study drug (Up to approximately 9 weeks)

07

Results

Posted Feb 4, 2019
Limitations and caveats
The study was terminated early due to business reasons.

Participant flow

Participant flow — Overall Study
MilestoneMK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mg
Started3362
Completed0000
Not completed3362
Withdrew: Death1250
Withdrew: Physician decision0001
Withdrew: Study terminated by sponsor2111

Outcome measures

PrimaryPercentage of Participants With a Dose Limiting Toxicity (DLT)

The occurrence of any of the following toxicities during Cycle 1 (Days 1-21), if assessed by the Investigator to be possibly, probably or definitely related to MK-1966 or SD-101, was considered a DLT: 1. Grade (Gr) 4 non-hematologic toxicity; 2. Gr 4 hematologic toxicity lasting \>7 days, except thrombocytopenia: \*Gr 4 thrombocytopenia of any duration; \*Gr 3 thrombocytopenia if associated with bleeding; 3. Gr 3 non-hematologic toxicity lasting \>3 days despite optimal supportive care; 4. Any Gr 3 or Gr 4 non-hematologic laboratory abnormality, if: medical intervention is required OR abnormality leads to hospitalization OR abnormality persists for \>1 week; 5. Febrile neutropenia Gr 3 or Gr 4; 6. Any drug-related AE which caused participant to discontinue study drug during Cycle 1 7. Gr 5 toxicity; or 8. Delay in initiation of Cycle 2 for \>2 weeks due to study drug-related toxicity. The percentage of participants who experienced a DLT during Cycle 1 is presented.

Time frame:
From time of first dose of study drug to the end of Cycle 1. Each cycle was 21 days. (Up to 21 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Dose Limiting Toxicity (DLT)
Percentage of ParticipantsMK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mg
Percentage of Participants With a Dose Limiting Toxicity (DLT)0.0 (0.0 to 33.1)0.0 (0.0 to 33.1)20.0 (5.1 to 44.8)0.0 (0.0 to 41.5)
PrimaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered study drug and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study drug, was also an AE. The number of participants who experienced as AE is presented.

Time frame:
From first dose of study drug through 90 days after last dose of study drug (Up to approximately 22 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsMK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mg
Number of Participants With Adverse Events (AEs)3362
PrimaryNumber of Participants Discontinuing Study Drug Due to AEs

The number of participants who discontinued study drug due to an AE is presented.

Time frame:
From first dose of study drug up to last dose of study drug (Up to approximately 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to AEs
ParticipantsMK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mg
Number of Participants Discontinuing Study Drug Due to AEs0010

Adverse events

Collected over From first dose of study drug through 90 days after last dose of study drug (Up to approximately 22 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-1966 70 mg+SD-101 1 mg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
MK-1966 70 mg+SD-101 4 mg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
MK-1966 210 mg+SD-101 4 mg5/6 (83.3%)3/6 (50%)6/6 (100%)
MK-1966 700 mg+SD-101 4 mg0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventMK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mg
Skin infectionInfections and infestations0/30/30/61/2
PyrexiaGeneral disorders1/30/30/60/2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/31/30/60/2
Urinary tract infectionInfections and infestations0/30/31/60/2
HyponatraemiaMetabolism and nutrition disorders0/30/31/60/2
HypotensionVascular disorders0/30/31/60/2
Most frequent other events
Showing 10 of 81
Most frequent other events
EventMK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mg
StomatitisGastrointestinal disorders2/30/32/60/2
VomitingGastrointestinal disorders0/32/32/61/2
ChillsGeneral disorders1/32/32/60/2
FatigueGeneral disorders1/32/33/61/2
Mucosal inflammationGeneral disorders1/32/31/61/2
PyrexiaGeneral disorders2/30/32/60/2
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/32/30/60/2
CoughRespiratory, thoracic and mediastinal disorders0/32/31/61/2
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/32/30/60/2
PericarditisCardiac disorders0/30/30/61/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mgTotal
Mean64.7 ± 1.563.0 ± 6.963.7 ± 6.850.5 ± 2.161.9 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)MK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mgTotal
Female30317
Male03317
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-1966 70 mg+SD-101 1 mgMK-1966 70 mg+SD-101 4 mgMK-1966 210 mg+SD-101 4 mgMK-1966 700 mg+SD-101 4 mgTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White336214
More than one race00000
Unknown or Not Reported00000
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Jan 2018, 18 months.

Results were first posted in Feb 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2016
First posted
Apr 7, 2016
StartActual
Jun 22, 2016
Primary completionActual
Jan 8, 2018
CompletionActual
Jan 8, 2018
Results first posted
Feb 4, 2019
Last update
Feb 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02731742
Responsible party
Sponsor
First posted
Apr 7, 2016
Start date
Jun 22, 2016
Primary completion
Jan 8, 2018
Completion
Jan 8, 2018
Results posted
Feb 4, 2019
Last update
Feb 4, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion